Status:

COMPLETED

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions:

Obesity

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.

Detailed Description

The prevalence of obesity is increasing worldwide. Obesity and being overweight are major risk factors for chronic cardiovascular disease, type 2 diabetes mellitus, hypertension and stroke, and certai...

Eligibility Criteria

Inclusion

  • BMI \>=30 kg/m2 and \<50 kg/m2 or a BMI \>=27 kg/m2 and \<50 kg/m2 in the presence of controlled hypertension and/or treated or untreated dyslipidemia
  • Must have a stable weight, i.e., increasing or decreasing not more than 5% in the 3 months before screening
  • Serum creatinine \<=1.5 mg/dL for men and \<=1.4 mg/dL for women at screening
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 2 times the upper limit of normal (ULN) and bilirubin within the normal range, unless the findings are consistent with Gilbert's disease
  • fasting plasma glucose PG \<7.0 mmol/L (126 mg/dL) at screening

Exclusion

  • A history of hereditary glucose-galactose malabsorption or primary renal glycosuria
  • An established diagnosis of diabetes mellitus or treatment with glucose lowering drugs at screening
  • A history of reactive hypoglycemia or of symptomatology possibly due to hypoglycemia
  • Fasting triglyceride level \>6.78 mmol/L (600 mg/dL) at screening
  • History of obesity with a known cause (e.g., Cushing's disease)

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2008

Estimated Enrollment :

376 Patients enrolled

Trial Details

Trial ID

NCT00650806

Start Date

May 1 2008

End Date

September 1 2008

Last Update

May 24 2013

Active Locations (36)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (36 locations)

1

Hot Springs, Arkansas, United States

2

Walnut Creek, California, United States

3

Westlake Village, California, United States

4

Destin, Florida, United States